Processing your payment...
Please do not close your browser.

Bispecific Antibody Market- Global Growth, Trends and Forecast (2022 - 2029) By Drug Type (Blinatumab, Catumaxomab, Duligotumab) By Indication (Cancer, Infectious Disease, Inflammatory, CNS Disorders) and By Regions

28 Jun, 2022 | 112 Pages
Shares
facebook sharing button
linkedin sharing button
twitter sharing button
sharethis sharing button

Over the forecast period, the Bispecific Antibody Market will register a CAGR of 100% in terms of revenue and the global market size will reach USD 1 Billion by 2029.

Bispecific Antibody Market Overview

The monoclonal antibody industry's distinctive successes led to the development of a new wave of antibody market known as the Bispecific cancer antibody market. Bispecific cancer antibody market applications have pushed oncology researchers to double the healthcare advantages acquired by patients suffering from various forms of tumors in a very urgent and novel approach. Targeting two particular molecules located on the surface of cancer antigens is the whole approach followed by the medications now on the market. The same has been confirmed in a variety of preclinical and clinical settings, indicating that the therapeutic market is poised to give excellent healthcare outcomes to patients who have developed resistance to existing treatments.

In one molecule, bispecific antibodies have two antigen-binding sites. Bispecific antibodies appear in a variety of sizes and shapes, ranging from tiny proteins with two connected antigen-binding fragments to giant immunoglobulin G (IgG)-like molecules with additional domains attached.

Bispecific antibodies (bsAbs) combine the specificities of two antibodies to simultaneously target different antigens or epitopes. BsAbs that have a 'two target' capability can attach to several receptors or ligands on the cell surface. BsAbs can also bring targets to close together, either to assist in the formation of protein complexes on a single cell or to initiate cell-to-cell interaction. The global need for bispecific antibodies is being bolstered by new techniques and their use in a variety of illness treatments, among other things. In addition, bispecific antibody assays are being employed in the detection of SARS-CoV. This test outperformed the standard monoclonal ELISA-based assay. The use of bispecific antibodies to identify Covid-19 infections has the potential to move the bispecific antibody industry ahead.

What is our Bispecific Antibody Market report scope?

 

Report Attributes

 

 

Report Details

 

Forecast Period 2022 to 2029

 

CAGR of 100 % during the review period (2022 to 2029).

 

By Drug Type

  • Blinatumab
  • Catumaxomab
  • Duligotumab

 

By Application

 

 

 

 

  • Cancer
  • Infectious Disease
  • Inflammatory and Autoimmune Disorders
  • CNS Disorders

 

By End-User

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

 

 

 

By Companies

  • F. Hoffmann-La Roche Ltd
  • GenScript
  • Sino Biological Inc.
  • Creative-Biolabs
  • AbbVie Inc.
  • Kymab
  • AstraZeneca
  • BIOCYTOGEN
  • Amgen Inc.
  • Pfizer Inc.
  • Novartis AG
  • Johnson & Johnson
  • ProteoGenix

 

 

 

Regions Covered

 

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

 

 

 

 

 

 

 

 

Countries Covered

  • US
  • Canada
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • Middle East & Africa
  • Latin America

 

Historical Year

 

 

2017 to 2021

Forecast Year

 

2022 to 2029

Number of Pages

112

 

Customization Available

 

 

Yes, the report can be customized as per your needs

Who are the Major Players in Bispecific Antibody Market?

Market Growth Reports lists out all the Bispecific Antibody Market companies that are presently striving to reduce the impact of Covid-19 pandemic on the Market- F. Hoffmann-La Roche Ltd, GenScript, Sino Biological Inc., Creative-Biolabs, AbbVie Inc., Kymab, AstraZeneca, BIOCYTOGEN, Amgen Inc., Pfizer Inc., Novartis AG, Johnson & Johnson, ProteoGenix, Others

Industry News:

Amgen To Acquire Privately Held Teneobio for $900 Million In Cash with Future Contingent Milestone Payments

Acquisition Includes a Portfolio of Early-Stage Oncology Assets, Including a Phase 1 Bispecific Antibody for Patients with Advanced Prostate Cancer. THOUSAND OAKS, Calif. and NEWARK, Calif., July 27, 2021 - Amgen (NASDAQ: AMGN) and Teneobio today announced an agreement under which Amgen will acquire Teneobio, a privately held, clinical stage biotechnology company developing a new class of biologics called Human Heavy-Chain Antibodies.  Under the terms of the agreement, Amgen will acquire all outstanding shares of Teneobio at closing in exchange for a $900 million upfront cash payment, as well as future contingent milestone payments to Teneobio equity holders potentially worth up to an additional $1.6 billion in cash.

What are the major Drug Type, Application,s and End Users for Bispecific Antibody Market?

By Drug Type, it is segmented into

  • Blinatumab
  • Catumaxomab
  • Duligotumab

By Application it is segmented into

  • Anti-inflammatories
  • Bronchodilators
  • Ectoparasiticides
  • Endoparasiticides

By End User, it is segmented into

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

Bispecific Antibody Market Regional Analysis

Because of the rising number of cancer patients and the region's well-developed healthcare infrastructure, North America is predicted to lead the worldwide bispecific antibody market. Melanoma was responsible for around 92 percent of new cases of skin cancer and 69 percent of skin cancer-related fatalities in the United States in 2018, according to the Journal of Technology in Cancer Research and Treatment. The second category includes leukaemia and gastrointestinal cancers. Because of the rising number of cancer patients, the growing elderly population, and increased investment in this sector, Europe is likely to see considerable development in this market. Bispecific antibodies are an effective technique to cure illnesses by assisting in the enhancement of immunity.

 

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Rest of the World
    • Middle East & Africa
    • Latin America
  1. INTRODUCTION
    • MARKET DEFINITION
    • MARKET DYNAMICS
    • MARKET SEGMENTATION
    • REPORT TIMELINES
    • KEY STAKEHOLDERS
  2. RESEARCH METHODOLOGY
    • DATA MINING
      • SECONDARY RESEARCH
      • PRIMARY RESEARCH
      • SUBJECT MATTER EXPERT ADVICE
    • QUALITY CHECK
    • FINAL REVIEW
      • DATA TRIANGULATION
      • BOTTOM-UP APPROACH
      • TOP-DOWN APPROACH
      • RESEARCH FLOW
  3. EXECUTIVE SUMMARY
    • INTRODUCTION
    • GLOBAL BISPECIFIC ANTIBODY MARKET BY DRUG TYPES
    • GLOBAL BISPECIFIC ANTIBODY MARKET BY APPLICATION
    • GLOBAL BISPECIFIC ANTIBODY MARKET BY END-USER
  4. MARKET DYNAMICS
    • DRIVERS
      • INCREASING GERIATRIC POPULATION AND PREVALENCE OF CHRONIC DISEASE
    • RESTRAINTS
      • STRINGENT ENVIRONMENTAL REGULATIONS
      • HIGH COST OF MATERIALS
    • OPPORTUNITIES
      • BISPECIFIC ANTIBODY GROWTH
    • APPLICATION OF BISPECIFIC ANTIBODY IMPACT OF COVID 19
  5. GLOBAL BISPECIFIC ANTIBODY MARKET, BY DRUG TYPES
    • INTRODUCTION
    • BLINATUMAB
    • CATUMAXOMAB
    • DULIGOTUMAB
  6. GLOBAL BISPECIFIC ANTIBODY MARKET, BY APPLICATION
    • INTRODUCTION
    • CANCER
    • INFECTIOUS DISEASE
    • INFLAMMATORY AND AUTOIMMUNE DISORDERS
    • CNS DISORDERS
  7. GLOBAL BISPECIFIC ANTIBODY MARKET, BY END-USER
    • INTRODUCTION
    • HOSPITAL PHARMACIES
    • RETAIL PHARMACIES
    • ONLINE PHARMACIES
  8. GLOBAL BISPECIFIC ANTIBODY MARKET, BY REGION
    • NORTH AMERICA
      • US
      • CANADA
      • MEXICO
    • EUROPE
      • GERMANY
      • FRANCE
      • UK
      • ITALY
      • RUSSIA
      • REST OF EUROPE
    • APAC
      • CHINA
      • SOUTH KOREA
      • JAPAN
      • INDIA
      • AUSTRALIA
      • ASEAN
      • REST OF APAC
    • MIDDLE EAST AND AFRICA
      • SAUDI ARABIA
      • UAE
      • SOUTH AFRICA
      • TURKEY
      • REST OF MEA
    • SOUTH AMERICA
      • BRAZIL
      • REST OF MEA
      • ARGENTINA
      • REST OF SOUTH AMERICA
  9. COMPETITIVE LANDSCAPE
    • MERGERS, ACQUISITIONS, JOINT VENTURES, COLLABORATIONS,
    • AND AGREEMENTS
      • KEY DEVELOPMENT
    • MARKET SHARE PERCENT/RANKING ANALYSIS
    • STRATEGIES ADOPTED BY LEADING PLAYERS
  10. COMPANY PROFILES
    • BUSINESS OVERVIEW
    • COMPANY SNAPSHOT
    • PRODUCT BENCHMARKING
    • STRATEGIC INITIATIVES
  1. F. HOFFMANN-LA ROCHE LTD
  2. GENSCRIPT
  3. SINO BIOLOGICAL INC.
  4. CREATIVE-BIOLABS
  5. ABBVIE INC.
  6. KYMAB
  7. ASTRAZENECA
  8. BIOCYTOGEN
  9. AMGEN INC.
  10. PFIZER INC.
  11. NOVARTIS AG
  12. JOHNSON & JOHNSON
  13. PROTEOGENIX

 

 

SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.

Request A Sample

Please Choose License Type

  • Single User License
    $2500
  • Site License
    $3000
  • Global License
    $5000

How can we help you?

Reach us with your research requirements and we shall provide the optimum solution to suit your needs.

Curioust about Multiple Reports?

Discounts available for multiple report purchases.

Contact Us

Our Clients

  • Korean Institute of Tuberculosis
  • Sanyo chemical Industries LTD
  • Novartis
  • Hisamitsu
  • Pfizer
  • AbbVie
  • RevHealth
  • Zeon Corporation
  • Abbott (Established Pharmaceutical Products)
  • Sinopharm (pharmaceutical distribution segment)
  • Takeda Pharmaceutical
  • Gilead Sciences
  • Sartorius
  • Zavation
  • Permobil
  • Ansell
  • Cefla